Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Clovis Oncology 

1871 Folsom Street

Boulder  Colorado  80302  U.S.A.
Phone: n/a Fax: n/a


 Company News
Clovis Oncology (CLVS) Receives Breakthrough Therapy Designation For Rucaparib For Monotherapy Treatment Of Advanced Ovarian Cancer In Patients With BRCA-Mutated Tumors (Inclusive Of Both Germline And Somatic BRCA Mutations) 4/7/2015 10:07:18 AM
Clovis Oncology (CLVS) Shares Leap as FDA Deems Ovarian Cancer Drug a Breakthrough, Company Preps for ARIEL3 4/7/2015 7:37:52 AM
Clovis Oncology (CLVS) Announces 2014 Operating Results 2/26/2015 11:36:38 AM
Clovis Oncology (CLVS) To Announce Fourth Quarter/Year-End 2014 Financial Results And Host Webcast Conference Call On February 25 2/18/2015 1:46:23 PM
Clovis Oncology (CLVS) To Present At The 2015 Leerink Global Healthcare Conference 2/4/2015 10:28:58 AM
Clovis Oncology (CLVS) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/6/2015 11:32:34 AM
Clovis Oncology (CLVS) Release: Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And Brcaness Patients 11/20/2014 9:21:39 AM
Clovis Oncology (CLVS) Release: Interim Data From Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling And Durable Clinical Activity And Progression-Free Survival (PFS) In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 11/19/2014 12:14:36 PM
Clovis Oncology (CLVS) Rises On News Of GlaxoSmithKline (GSK) Oncology Collaboration 11/18/2014 7:59:35 AM
Clovis Oncology (CLVS) Announces First Patient Enrolled In TIGER-1 Study 11/13/2014 10:53:56 AM